$1.6413
-0.0387[-2.30%]
At close: Apr 25
$1.6413
0[0.00%]
After Hours: 5:54PM EDT
CARISMA Therapeutics
(NASDAQ:CARM)CARISMA Therapeutics Stock (NASDAQ:CARM), Analyst Ratings, Price Targets, Predictions
CARISMA Therapeutics Inc has a consensus price target of $9.4, established from looking at the 11 latest analyst ratings. The last 3 analyst ratings were released from BTIG, HC Wainwright & Co., and HC Wainwright & Co. on April 11, 2024, April 2, 2024, and November 29, 2023. With an average price target of $8.67 between BTIG, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 428.04% upside for CARISMA Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
BTIG
HC Wainwright & Co.
Capital One
Evercore ISI Group
Baird
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for CARISMA Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/11/2024 | CARM | Buy Now | CARISMA Therapeutics | $1.64 | 265.56% | BTIG | Justin Zelin | → $6 | Initiates | → Buy | Get Alert |
| 04/02/2024 | CARM | Buy Now | CARISMA Therapeutics | $1.64 | 448.35% | HC Wainwright & Co. | Mitchell Kapoor | $11 → $9 | Maintains | Buy | Get Alert |
| 11/29/2023 | CARM | Buy Now | CARISMA Therapeutics | $1.64 | 570.2% | HC Wainwright & Co. | Mitchell Kapoor | → $11 | Reiterates | Buy → Buy | Get Alert |
| 10/03/2023 | CARM | Buy Now | CARISMA Therapeutics | $1.64 | 509.27% | Capital One | Naureen Quibria | → $10 | Initiates | → Overweight | Get Alert |
| 09/06/2023 | CARM | Buy Now | CARISMA Therapeutics | $1.64 | 570.2% | HC Wainwright & Co. | Mitchell Kapoor | → $11 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | CARM | Buy Now | CARISMA Therapeutics | $1.64 | 570.2% | HC Wainwright & Co. | Mitchell Kapoor | $10 → $11 | Maintains | Buy | Get Alert |
| 07/06/2023 | CARM | Buy Now | CARISMA Therapeutics | $1.64 | 631.13% | Evercore ISI Group | Liisa Bayko | → $12 | Initiates | → Outperform | Get Alert |
| 06/29/2023 | CARM | Buy Now | CARISMA Therapeutics | $1.64 | 509.27% | HC Wainwright & Co. | Mitchell Kapoor | → $10 | Reiterates | Buy → Buy | Get Alert |
| 06/28/2023 | CARM | Buy Now | CARISMA Therapeutics | $1.64 | 509.27% | Baird | Jack Allen | → $10 | Reiterates | Outperform → Outperform | Get Alert |
| 05/24/2023 | CARM | Buy Now | CARISMA Therapeutics | $1.64 | 509.27% | HC Wainwright & Co. | Mitchell Kapoor | → $10 | Initiates | → Buy | Get Alert |
| 04/14/2023 | CARM | Buy Now | CARISMA Therapeutics | $1.64 | 509.27% | Baird | Jack Allen | → $10 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for CARISMA Therapeutics (CARM)?
The latest price target for CARISMA Therapeutics (NASDAQ: CARM) was reported by BTIG on April 11, 2024. The analyst firm set a price target for $6.00 expecting CARM to rise to within 12 months (a possible 265.56% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for CARISMA Therapeutics (CARM)?
The latest analyst rating for CARISMA Therapeutics (NASDAQ: CARM) was provided by BTIG, and CARISMA Therapeutics initiated their buy rating.
When was the last upgrade for CARISMA Therapeutics (CARM)?
There is no last upgrade for CARISMA Therapeutics.
When was the last downgrade for CARISMA Therapeutics (CARM)?
There is no last downgrade for CARISMA Therapeutics.
When is the next analyst rating going to be posted or updated for CARISMA Therapeutics (CARM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CARISMA Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CARISMA Therapeutics was filed on April 11, 2024 so you should expect the next rating to be made available sometime around April 11, 2025.
Is the Analyst Rating CARISMA Therapeutics (CARM) correct?
While ratings are subjective and will change, the latest CARISMA Therapeutics (CARM) rating was a initiated with a price target of $0.00 to $6.00. The current price CARISMA Therapeutics (CARM) is trading at is $1.64, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.